Cover Image
Market Research Report

Rheumatoid Arthritis Pricing, Reimbursement & Market Access 2018: US, Canada, UK, Germany, France, Italy, Spain, Japan, Australia, Brazil, Russia, China, India

Published by Visiongain Ltd Product code 632845
Published Content info 333 Pages
Delivery time: 1-2 business days
Price
Back to Top
Rheumatoid Arthritis Pricing, Reimbursement & Market Access 2018: US, Canada, UK, Germany, France, Italy, Spain, Japan, Australia, Brazil, Russia, China, India
Published: March 29, 2018 Content info: 333 Pages
Description

Title:
Rheumatoid Arthritis Pricing, Reimbursement & Market Access 2018
US, Canada, UK, Germany, France, Italy, Spain, Japan, Australia, Brazil, Russia, China, India.

This report provides analysis and evaluation of the current and potential economic burden of Rheumatoid Arthritis (RA) in the major regions of the world comprising North America, Europe (EU5), Asia-Pacific and BRIC markets. The report also outlines the historical and current healthcare status for the selected markets with respect to the expenditures and the health system that govern medical access. With the increased competition in the RA market resulting from the biosimilar race and new biologic entrants such as the JAK inhibitors and IL-6 inhibitors, payers now have the leverage to enact on the cost-containment of the drug category that has been experiencing high unit cost increases year after year. The blockbuster drugs of the anti-TNF category such as, Humira and Enbrel along with Remicade have been the market leaders in RA treatment since their launch however the rising biosimilars especially to Remicade and Enbrel are posing threats to their global market shares.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new report you find 333-page report you will receive 53 tables and 88 figures - all unavailable elsewhere.

The 333-page report provides clear detailed insight into the Rheumatoid Arthritis Pricing, Reimbursement & Market Access. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Provides a brief history of rheumatoid arthritis, treatment options, marketed drugs and pipeline products.
  • Discusses the global pricing & reimbursement for therapeutic drugs, factors affecting pricing & reimbursement, price negotiations & discounts and reimbursement policies.
  • Discusses Health Economics and Outcomes Research (HEOR), Economic Value Planning, Cost-Effectiveness analysis as well as patent expiry and effects on pricing.
  • Discusses Health Technology Assessment (HTA) in market access, key benefits of HTA, HTA regulatory agencies.
  • Discusses the healthcare system, healthcare expenditure, key formularies, role of pharmacists, regulatory & approval process, pricing & reimbursement process, HTA, cost of rheumatoid arthritis treatment and payer insight, of these national markets:
    • The US
    • Canada
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Japan
    • Australia
    • Brazil
    • Russia
    • India
    • China
  • Discusses parallel import in the US and Europe

Visiongain's study is intended for anyone requiring commercial analyses for the Rheumatoid Arthritis Pricing, Reimbursement & Market Access. You find data, trends and predictions.

Buy our report today Rheumatoid Arthritis Pricing, Reimbursement & Market Access 2018: US, Canada, UK, Germany, France, Italy, Spain, Japan, Australia, Brazil, Russia, China, India.

Visiongain is a trading partner with the US Federal Government.

Table of Contents
Product Code: PHA0297

Table of Contents

1. Report Overview

  • 1.1. How This Study Delivers
  • 1.2. Method of Research and Analysis
  • 1.3. Frequently Asked Questions (FAQs)
  • 1.4. Associated Visiongain Reports
  • 1.5. About Visiongain

2. Market Overview

  • 2.1. A Brief History of Rheumatoid Arthritis and Treatments
  • 2.2. Rheumatoid Arthritis: Treatment and Prevention
  • 2.3. Marketed RA drugs in Major Countries
  • 2.4. Pipeline Products

3. Global Pricing & Reimbursement of Therapeutic Drugs

  • 3.1. Factors Affecting Pricing & Reimbursement Decision
  • 3.2. Price Negotiations & Discounts
  • 3.3. Pricing of a New Drug
  • 3.4. Reimbursement Policies

4. Economic Evaluations

  • 4.1. Role of HEOR and Economic Value Planning
  • 4.2. Overview of Cost-Effectiveness Analysis
  • 4.3. Drug Patent Expiry & Effects on Pricing

5. Health Technology Assessment (HTA) in Market Access

  • 5.1. Key Benefits of HTA and its Process
  • 5.2. Principle HTA Regulatory Agencies
  • 5.3. Case Study: Brief About United Kingdom's NICE

6. Global Pharmaceutical Market Dynamics

  • 6.1. United States (U.S.)
    • 6.1.1. U.S. Healthcare System
      • 6.1.1.1. Healthcare Expenditure
      • 6.1.1.2. Key Formularies
      • 6.1.1.3. Role of Pharmacists in U.S. Healthcare System
      • 6.1.1.4. Regulatory and Approval Process
    • 6.1.2. Pricing & Reimbursement Process and HTA
    • 6.1.3. Rheumatoid Arthritis Cost of Treatment in United States
    • 6.1.4. United States' Payer Insights
    • 6.1.5. Features of RA in United States
  • 6.2. Canada
    • 6.2.1. Canada Healthcare System
      • 6.2.1.1. Healthcare Expenditure:
      • 6.2.1.2. Health Coverage:
      • 6.2.1.3. Key Formularies:
      • 6.2.1.4. Role of Pharmacists in Canada Healthcare System
    • 6.2.2. Pricing of Pharmaceuticals in Canada
      • 6.2.2.1. Drug Pricing Amendment in Canada
      • 6.2.2.2. Reimbursement in Canada
    • 6.2.3. Health Technology Assessment
    • 6.2.4. Rheumatoid Arthritis Cost of Treatment
    • 6.2.5. Canada Payer Insight
    • 6.2.6. Features of Canadian Health care for Rheumatoid Arthritis
  • 6.3. Europe (EU5)
    • 6.3.1. United Kingdom
      • 6.3.1.1. United Kingdom Healthcare System
        • 6.3.1.1.1. Healthcare Expenditure:
        • 6.3.1.1.2. Health Coverage:
        • 6.3.1.1.3. Key Formularies:
        • 6.3.1.1.4. Role of Pharmacists in U.K. Healthcare System
      • 6.3.1.2. Pricing & Reimbursement
        • 6.3.1.2.1. Pricing of Pharmaceuticals in the U.K.
        • 6.3.1.2.2. Reimbursement of Pharmaceuticals in the U.K.
      • 6.3.1.3. Health Technology Assessment
      • 6.3.1.4. Rheumatoid Arthritis Cost of Treatment
      • 6.3.1.5. U.K. Payer Insight
      • 6.3.1.6. Features of Rheumatoid Arthritis in U.K.
    • 6.3.2. Germany
      • 6.3.2.1. Germany Healthcare System
        • 6.3.2.1.1. Key Organizations in German Healthcare System
        • 6.3.2.1.2. Healthcare Expenditure:
        • 6.3.2.1.3. Health Coverage:
        • 6.3.2.1.4. Key Formularies:
        • 6.3.2.1.5. Role of Pharmacists in German Healthcare System
      • 6.3.2.2. Pricing & Reimbursement
      • 6.3.2.3. Health Technology Assessment
        • 6.3.2.3.1. Regulatory & Approval Process
      • 6.3.2.4. Rheumatoid Arthritis Cost of Treatment in Germany
      • 6.3.2.5. Cost of Treatment
      • 6.3.2.6. Germany's Payer Insights
      • 6.3.2.7. Features of RA in Germany
    • 6.3.3. France
      • 6.3.3.1. France Healthcare System
        • 6.3.3.1.1. Healthcare Expenditure
        • 6.3.3.1.2. Health Coverage
        • 6.3.3.1.3. Key formularies
        • 6.3.3.1.4. Role of Pharmacists in France Healthcare System
      • 6.3.3.2. Pricing & Reimbursement:
        • 6.3.3.2.1. Reimbursement Process
        • 6.3.3.2.2. Pricing of Pharmaceuticals
      • 6.3.3.3. Health Technology Assessment
      • 6.3.3.4. Rheumatoid Arthritis Cost of Treatment in France
      • 6.3.3.5. France Payer's Insight
      • 6.3.3.6. Features of RA in France
    • 6.3.4. Italy
      • 6.3.4.1. Italy Healthcare System
        • 6.3.4.1.1. Healthcare Expenditure
        • 6.3.4.1.2. Health Coverage
        • 6.3.4.1.3. Key Formularies
        • 6.3.4.1.4. Role of Pharmacists in Italy Healthcare System
      • 6.3.4.2. Pricing & Reimbursement
        • 6.3.4.2.1. Reimbursement Process
        • 6.3.4.2.2. Pricing Approval Process
      • 6.3.4.3. Health Technology Assessment
      • 6.3.4.4. Rheumatoid Arthritis Cost of Treatment in Italy
      • 6.3.4.5. Features of RA in Italy
    • 6.3.5. Spain
      • 6.3.5.1. Spain Healthcare System
        • 6.3.5.1.1. Healthcare Expenditure:
        • 6.3.5.1.2. Health Coverage:
        • 6.3.5.1.3. Key Formularies:
        • 6.3.5.1.4. Role of Pharmacists in Spain Healthcare System
      • 6.3.5.2. Pricing & Reimbursement
        • 6.3.5.2.1. Reimbursement of Pharmaceuticals in Spain
        • 6.3.5.2.2. Pricing of Pharmaceuticals in Spain
      • 6.3.5.3. Health Technology Assessment
      • 6.3.5.4. Rheumatoid Arthritis Cost of Treatment in Spain
      • 6.3.5.5. Cost of Treatment
      • 6.3.5.6. Spain Payer Insight
      • 6.3.5.7. Features of Spanish Health care for Rheumatoid Arthritis
  • 6.4. Asia-Pacific
    • 6.4.1. Japan
      • 6.4.1.1. Japan Healthcare System
        • 6.4.1.1.1. Key Formularies
      • 6.4.1.2. Pricing & Reimbursement
      • 6.4.1.3. Health Technology Assessment:
      • 6.4.1.4. Rheumatoid Arthritis Cost of Treatment in Japan
      • 6.4.1.5. Japan Payer's Insight
      • 6.4.1.6. Features of RA in Japan
    • 6.4.2. Australia
      • 6.4.2.1. Australia Healthcare System
        • 6.4.2.1.1. Healthcare Expenditure:
        • 6.4.2.1.2. Health Coverage:
        • 6.4.2.1.3. Key Formularies:
        • 6.4.2.1.4. Role of Pharmacists in Australian Healthcare System:
      • 6.4.2.2. Pricing & Reimbursement
      • 6.4.2.3. Health Technology Assessment
        • 6.4.2.3.1. Regulatory and Approval Process
      • 6.4.2.4. Rheumatoid Arthritis Cost of Treatment in Australia
      • 6.4.2.5. Australia's Payer's Insight
      • 6.4.2.6. Features of Australian Health care for Rheumatoid Arthritis
  • 6.5. BRIC
    • 6.5.1. Brazil
      • 6.5.1.1. Brazilian Healthcare System
        • 6.5.1.1.1. Role Pharmacists in Brazilian Healthcare System
      • 6.5.1.2. Regulatory Process
        • 6.5.1.2.1. ANVISA's Regulatory framework for biological products
      • 6.5.1.3. Brazil Pricing and Reimbursement
        • 6.5.1.3.1. Pricing Process
        • 6.5.1.3.2. Reimbursement Process
      • 6.5.1.4. Health Technology Assessment
      • 6.5.1.5. Cost of Rheumatoid arthritis in Brazil
      • 6.5.1.6. Brazil Payer's Insight
      • 6.5.1.7. Features of RA in Brazil
    • 6.5.2. Russia
      • 6.5.2.1. Russia Healthcare System
        • 6.5.2.1.1. Healthcare Expenditure
      • 6.5.2.2. Pricing & Reimbursement
      • 6.5.2.3. Health Technology Assessment:
      • 6.5.2.4. Russia Payer's Insight
      • 6.5.2.5. Features of RA in Russia
    • 6.5.3. India
      • 6.5.3.1. India Healthcare System
      • 6.5.3.2. Pricing & Reimbursement
        • 6.5.3.2.1. Pricing of pharmaceuticals in India
        • 6.5.3.2.2. Reimbursement of Pharmaceuticals in India
      • 6.5.3.3. Cost of RA treatment in India
      • 6.5.3.4. India Payer Insight
      • 6.5.3.5. Features of RA in India
    • 6.5.4. China
      • 6.5.4.1. China Healthcare System
        • 6.5.4.1.1. Healthcare Expenditure
        • 6.5.4.1.2. Health Insurance & Coverage in China
      • 6.5.4.2. Pricing & Reimbursement:
        • 6.5.4.2.1. Pricing of Pharmaceuticals in China
        • 6.5.4.2.2. Reimbursement of Pharmaceuticals in China
      • 6.5.4.3. Health Technology Assessment (HTA):
      • 6.5.4.4. Rheumatoid Arthritis Cost of Treatment in China
      • 6.5.4.5. China Payer's Insight
      • 6.5.4.6. Features of RA in China

7. Parallel Import & Its Impact

  • 7.1. Parallel Import in Europe
  • 7.2. Parallel Import in the U.S.
  • 7.3. Economic aspects in Parallel trade
  • 7.4. Parallel trade and Rheumatoid Arthritis
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 2.1: Diagnosis of RA: ACR/EULAR 2012 Criteria
  • Table 2.2: Biologics used in RA
  • Table 2.3: Biologics used in RA
  • Table 2.4: Availability of Key RA Treatments in 13 Major Markets
  • Table 2.5: Pipeline Treatments for Rheumatoid Arthritis
  • Table 2.6: Pipeline Biosimilars for Rheumatoid Arthritis
  • Table 3.1: VBP Value Metrics
  • Table 5.1: Institutions and Advisory Bodies Responsible for HTA Activities In EU
  • Table 6.1: U.S.: Average ASP for Biologic DMARDs
  • Table 6.2: U.S.: Medicare Payment Rate Per Unit, Remicade Vs. Biosimilars, 2016-2017
  • Table 6.3: Cost of Treatment in the U.S. for Anti-TNF drugs (WAC Prices) (USD)
  • Table 6.4: U.S.: Rheumatoid Arthritis Drugs Price Trend & Forecast (WAC Price in USD), 2016-2028
  • Table 6.5: U.S.: Drug Categories for the 2015 ACR recommendations for treatment of Rheumatoid Arthritis
  • Table 6.6: Canada: Rheumatoid Arthritis Drugs Price Trend & Forecast (CAD$), 2014-2028
  • Table 6.7: Key Reimbursement Stakeholders' in Canada
  • Table 6.8: Canada Competitor Pricing of Rheumatoid Arthritis Drugs - Unit Ex-factory Prices ($CAD) (2014-2017)
  • Table 6.9: Canada- Rheumatoid Arthritis Cost of Trearment ($CAD)
  • Table 6.10: Rheumatoid Arthritis: Tests, Diagnostic Value & Disease Activity Monitoring
  • Table 6.11: U.K.: Rheumatoid Arthritis Drugs Price Trend & Forecast (GBP), 2014-2028
  • Table 6.12: UK Competitor Pricing of Rheumatoid Arthritis Drugs - Unit Ex-Factory Prices (£) (2014-2017)
  • Table 6.13: Overall per annum economic burden of RA (UK)
  • Table 6.14: Rheumatoid Arthritis Cost of Treatment
  • Table 6.15: Germany: Rheumatoid Arthritis Drugs Price Trend & Forecast (Euro), 2016-2028
  • Table 6.16: Germany Competitor Pricing of Rheumatoid Arthritis Drugs - Unit Ex-Factory Prices (Euro) (2014-2017)
  • Table 6.17: Germany: Rheumatoid Arthritis Annual Treatment Cost, 2014-2017
  • Table 6.18: Reimbursement Rate
  • Table 6.19: France: Rheumatoid Arthritis Drugs Price Trend & Forecast (Euro) 2014-2028
  • Table 6.20: France Competitor Pricing of Rheumatoid Arthritis Drugs - Unit Ex-factory Prices (€) (2014-2017)
  • Table 6.21: France: Rheumatoid Arthritis Cost of Treatment
  • Table 6.22: Italy: Rheumatoid Arthritis Drugs Price Trend & Forecast (Euro), 2016-2028
  • Table 6.23: Italy Competitor Pricing of Rheumatoid Arthritis Drugs - Unit Ex-factory Prices (€) (2014-2017)
  • Table 6.24: Italy: Rheumatoid Arthritis Cost of Treatment
  • Table 6.25: Spain: Rheumatoid Arthritis Anti-TNF Drugs Price Trend & Forecast (Euro), 2016-2028
  • Table 6.26: Spain Competitor Pricing of Rheumatoid Arthritis Drugs - Unit Ex-factory Prices (Euro) 2014-2017
  • Table 6.27: Spain: Rheumatoid Arthritis Annual Treatment Cost, 2014-2017
  • Table 6.28: Japan: Rheumatoid Arthritis Drugs Price Trend & Forecast (¥), 2016-2028
  • Table 6.29: Japan: Competitor Pricing of Rheumatoid Arthritis Drugs - Unit Ex-factory Prices (¥) (2014-2017)
  • Table 6.30: Japan: Rheumatoid Arthritis Cost of Treatment
  • Table 6.31: Australia: Formulary Allocation for Rheumatoid Arthritis Drugs (F1/F2)
  • Table 6.32: Australia Competitor Pricing of Rheumatoid Arthritis Drugs - Unit Ex-factory Prices (AUD) (2014-2017)
  • Table 6.33: Australia: Arthritis Anti-TNF Drugs Price Trend & Forecast (AUD), 2016-2028
  • Table 6.34: Brazil: Rheumatoid Arthritis Drugs Price Trend & Forecast (BRL), 2016-2028
  • Table 6.35: Brazil Competitor Pricing of Rheumatoid Arthritis Drugs - Unit Ex-factory Prices (BRL) (2014-2017)
  • Table 6.36: Brazil: RA Medications available in the Brazilian Public Care System
  • Table 6.37: Russia: Rheumatoid Arthritis Drugs Price Trend & Forecast (Rubles), 2016-2028
  • Table 6.38: India: Rheumatoid Arthritis Drugs Price Trend & Forecast (INR), 2016-2028
  • Table 6.39: India: Cost and Dosage of available biologic DMARDs in India
  • Table 6.40: India Competitor Pricing of Rheumatoid Arthritis Drugs - Unit Ex-factory Prices (INR) (2014-2017)
  • Table 6.41: China Healthcare System: Stakeholders and Functions
  • Table 6.42: Healthcare Coverage and Insurance in China
  • Table 6.43: Number of Hospitals in China by Economic Classification and Hospital Level
  • Table 6.44: China Competitor Pricing of Rheumatoid Arthritis Drugs - Unit Ex-factory Prices (CNY) (2014-2017)
  • Table 6.45: China: Rheumatoid Arthritis Drugs Price Trend & Forecast (CNY), 2016-2028

List of Figures

  • Figure 5.1: Aspects of HTA for Different Technologies and Interventions
  • Figure 6.1: U.S.: Key Organizations in US Healthcare System
  • Figure 6.2: U.S. - Healthcare Expenditure (% of GDP Spending), 2014-2017
  • Figure 6.3: U.S. - National Expenditures (as of %GDP Spending), 2016
  • Figure 6.4: U.S.: Market Access Flow in United States
  • Figure 6.5: U.S.: Federally Funded Health Insurance Plans
  • Figure 6.6: U.S.: Top Anti-TNF Drugs Price Trend in U.S. (WAC Price in USD) (2014-2017)
  • Figure 6.7: U.S.: Rheumatoid Arthritis Drugs Price Trend & Forecast (WAC Price in USD), 2016-2028
  • Figure 6.8: Canada - Healthcare Structure
  • Figure 6.9: Canada - National Expenditures (as of %GDP Spending), 2016
  • Figure 6.10: Canada - Healthcare Expenditure (% of GDP Spending), 2014-2017
  • Figure 6.11: Pricing & Reimbursement in Canada
  • Figure 6.12: Canada: Rheumatoid Arthritis Drugs Price Trend & Forecast (CAD$), 2016-2028
  • Figure 6.13: Pathways to Reimbursement in Canada
  • Figure 6.14: Anti-TNF Drugs Price Trend in Canada
  • Figure 6.15: U.K. - Healthcare System Structure
  • Figure 6.16: U.K. - National Expenditures (as of %GDP Spending), 2013-2015
  • Figure 6.17: U.K. - Rheumatoid Arthritis Expenditure - 2015 ($ billion)
  • Figure 6.18: Pricing & Reimbursement in the U.K.
  • Figure 6.19: U.K.: Rheumatoid Arthritis Drugs Price Trend & Forecast (GBP), 2016-2028
  • Figure 6.20: Health Technology Assessment & Appraisal in the U.K.
  • Figure 6.21: Biosimilars Uptake: Infliximab & Etanercept
  • Figure 6.22: U.K.: Rheumatoid Arthritis Drugs Price Trend (GBP), 2014-2017
  • Figure 6.23: Germany - Healthcare System Structure
  • Figure 6.24: Key decision-makers in German Healthcare system
  • Figure 6.25: Germany - Healthcare Expenditure (% of GDP Spending), 2014-2017
  • Figure 6.26: Germany - Multi-player nature of German healthcare system
  • Figure 6.27: Pricing & Reimbursement in Germany
  • Figure 6.28: Germany: Rheumatoid Arthritis Drugs Price Trend & Forecast (Euro), 2016-2028
  • Figure 6.29: Germany Health Technology Assessment
  • Figure 6.30: Germany: Rheumatoid Arthritis - Top Anti-TNF Drugs Price Trend - Unit List Price
  • Figure 6.31: Germany: Rheumatoid Arthritis - Top Anti-TNF Drugs Price Trend - Unit Negotiated Price
  • Figure 6.32: France Healthcare System Structure
  • Figure 6.33: France - Healthcare Expenditure (% of GDP Spending), 2013-2016
  • Figure 6.34: France - National Expenditures (as of %GDP Spending), 2016
  • Figure 6.35: Pricing & Reimbursement in France
  • Figure 6.36: France: Rheumatoid Arthritis Drugs Price Trend & Forecast (Euro), 2016-2028
  • Figure 6.37: Health Technology Assessment in France
  • Figure 6.38: France: Drug review & Decision process:
  • Figure 6.39: Anti-TNF Drugs Price Trend
  • Figure 6.40: Italy Healthcare System Structure
  • Figure 6.41: Italy - Healthcare Expenditure (% of GDP Spending), 2014-2017
  • Figure 6.42: Italy - National Expenditures (as of %GDP Spending), 2016
  • Figure 6.43: Italy - Rheumatoid Arthritis Expenditure - 2017 ($ billion)
  • Figure 6.44: Pricing & Reimbursement in Italy
  • Figure 6.45: Italy: Rheumatoid Arthritis Drugs Price Trend & Forecast (Euro), 2016-2028
  • Figure 6.46: Anti-TNF Drugs Price Trend in Italy
  • Figure 6.47: Spain - Healthcare System Structure
  • Figure 6.48: Spain - Healthcare Expenditure (% of GDP Spending), 2014-2017
  • Figure 6.49: Spain - National Expenditures (% of GDP Spending), 2016
  • Figure 6.50: Pricing & Reimbursement in Spain
  • Figure 6.51: Reimbursement of pharmaceuticals in Spain
  • Figure 6.52: Spain: Rheumatoid Arthritis Drugs Price Trend & Forecast (Euro), 2016-2028
  • Figure 6.53: Health Technology Assessment in Spain
  • Figure 6.54: Spain: Rheumatoid Arthritis - Top Anti-TNF Drugs Price Trend
  • Figure 6.55: Japan - Healthcare Expenditure (% of GDP Spending), 2013-2016
  • Figure 6.56: Japan - National Expenditures (as of %GDP Spending), 2016
  • Figure 6.57: Japan Healthcare System Structure
  • Figure 6.58: Japan: Rheumatoid Arthritis Drugs Price Trend & Forecast (¥), 2016-2028
  • Figure 6.59: Health Technology Assessment in Japan
  • Figure 6.60: Anti-TNF Drugs Price Trend in Japan
  • Figure 6.61: Australia - Healthcare System Structure
  • Figure 6.62: Australia - Healthcare Expenditure (% of GDP Spending), 2014-2017
  • Figure 6.63: Health Technology Assessment & Regulatory and Approval Process in Australia
  • Figure 6.64: Australia: Rheumatoid Arthritis - Top Anti-TNF Drugs Price Trend
  • Figure 6.65: Australia: Rheumatoid Arthritis Drugs Price Trend & Forecast (Euro), 2016-2028
  • Figure 6.66: Brazil - Healthcare Expenditure (% of GDP Spending), 2013-2016
  • Figure 6.67: Key Decision-Makers in Brazilian Healthcare System
  • Figure 6.68: Brazil Regulatory Process
  • Figure 6.69: Brazil: ANVISA's Regulatory approval pathway for biological products
  • Figure 6.70: Brazil: Rheumatoid Arthritis Drugs Price Trend & Forecast (BRL), 2016-2028
  • Figure 6.71: Brazil: Top Anti-TNF Drug Price Trend
  • Figure 6.72: Russia Healthcare System Structure
  • Figure 6.73: Russia - Healthcare Expenditure (% of GDP Spending), 2013-2016
  • Figure 6.74: Russia - National Expenditures (as of % GDP Spending), 2016
  • Figure 6.75: Russia: Rheumatoid Arthritis Drugs Price Trend & Forecast (Rubles), 2016-2028
  • Figure 6.76: India - Healthcare Expenditure (% of GDP Spending), 2014-2017
  • Figure 6.77: India Healthcare System Structure
  • Figure 6.78: Key Decision-Makers in Indian Healthcare System
  • Figure 6.79: India: Rheumatoid Arthritis Drugs Price Trend & Forecast (Euro), 2016-2028
  • Figure 6.80: Anti-TNF Drugs Price Trend in India (2014-2017)
  • Figure 6.81: China: Healthcare System Structure
  • Figure 6.82: China - Healthcare Expenditure (% of GDP Spending), 2013-2016
  • Figure 6.83: China - National Expenditures (as of %GDP Spending), 2016
  • Figure 6.84: Pricing & Reimbursement in China
  • Figure 6.85: China: Rheumatoid Arthritis Drugs Price Trend & Forecast (CNY), 2016-2028
  • Figure 6.86: China: Health Technology Assessment
  • Figure 6.87: Anti-TNF Drugs Price Trend in China

Companies Listed

  • Abbott
  • AbbVie
  • Ablynx
  • Astellas
  • AstraZeneca
  • AVIVA Health Insurance
  • AXA
  • BMS
  • BUPA
  • Can-Fite BioPharma
  • Celltrion
  • Cipla
  • ClaimSecure
  • CVS Caremark
  • Eli Lilly
  • Empire Life
  • Express Script
  • Freedom Health Insurance
  • Galapagos
  • Gilead
  • Great West Life (GWL)
  • Green Shield
  • Helpucover Health Insurance
  • Janssen
  • Johnson & Johnson
  • Manulife
  • Medavie Blue Cross
  • Medicare International
  • MedImmune
  • Merck
  • Momenta Pharmaceuticals
  • MSD
  • National Friendly HealthCare
  • Pfizer
  • PruHealth
  • Roche
  • Saga Health Insurance
  • Sandoz
  • Sanford C. Bernstein & Company
  • Sanofi
  • Schering-Plough
  • Shanghai CP Guojian Pharmaceutical Co
  • Simply Health
  • TelusHealth
  • UCB
  • VitaerisBio
  • Wyeth

List of Organisations Mentioned in the Report:

  • Academia Nacional de Medicina
  • Academy of Managed Care (AMCP)
  • AGENAS (National Agency for Regional Health Services)
  • Agència d'Avaluació de Tecnologia i Recerca Mèdiques de Catalunya (CAHTA)
  • Agencia de Evaluación de Tecnologías Sanitarias de Andalucía (AETSA)
  • Agencia Espanola del Medicamento y Productos Sanitarios (AEMPS)
  • Agencia Laín Entralgo de Madrid
  • Agência Nacional de Saúde Suplementar (ANS)
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Agency for Healthcare Research and Quality (AHRQ)
  • Agenzia Italiana del Farmaco (AIFA)
  • All Wales Medicines Strategy Group (AWMSG)
  • American College of Rheumatology (ACR)
  • ASLs (Azienda Sanitaria Locale)
  • Asociación Artritis Reumatoide de la Rioja
  • Asociación Madrileña de Pacientes con Artritis Reumatoide
  • Australian Government Department of Health and Ageing (DHA)
  • Axencia de Avaliación de Tecnoloxías Sanitarias de Galicia
  • Blue Cross Blue Shield
  • BMJ Group
  • Bundesinstitut für Arzneimittel und Medizinische Produkte - BfArM
  • Caisse Primaire d'Assurance Maladie (CPAM)
  • Câmara de Regulação do Mercado de Medicamentos (CMED)
  • Canada's Common Drug Review
  • Canadian Agency for Drugs and Technologies in Health (CADTH)
  • Canadian Drug Expert Committee (CDEC)
  • Canadian Expert Drug Advisory Committee (CEDAC)
  • Central Drugs Standard Control Organization (CDSCO)
  • Centre for Disease Control and Prevention (CDC)
  • Centre for Drug Evaluation and Research (CDER)
  • Centres for Markets Authority (CMA)
  • Comissão de Incorporação de Tecnologias (CITEC)
  • Comissão Nacional de Incorporac, ão de Tecnologias no SUS (CONITEC)
  • Comité scientifique de l'évaluation des médicaments aux fins d'inscription (CSEMI)
  • Consejo Interterritorial del Servicio Nacional de Salud de España (CISNS)
  • Conselho Federal de Medicina (CFM)
  • Conselho Nacional de Saúde (CNS)
  • Conselho Nacional de Secretarias Municipais de Saúde (CONASEMS)
  • Conselho Nacional de Secretários de Saúd (CONASS)
  • Coordinadora nacional de Artritis (CONARTRITIS)
  • Cruz Vermelha Brasileira
  • Department of Health (DoH)
  • European League Against Rheumatism (EULAR)
  • First Nations and Inuit Health Branch
  • Food and Drug Administration (FDA)
  • French National Agency for Accreditation and Evaluation in Health (ANAES)
  • German Federal Ministry of Health
  • German Institute of Medical Documentation and Information (DIMDI)
  • German Medical Association (Bundesärztekammer)
  • German Ministry of Education and Research
  • German Rheumatism League (Deutsche Rheuma-Liga)
  • German Society for Rheumatology (Deutsche Gesellschaft für Rheumatologie)
  • Haute Autorité de Santé (HAS)
  • Health and Social Care Information Centre
  • Health Canada
  • Institute for Quality and Efficiency in Healthcare (IQWiG)
  • Instituto Aragonés de Ciencias de la Salud (IACS)
  • Instituto de Salud Carlos III-ISCIII
  • Interministerial Committee for Economic Planning (CIPE, Comitato Interministeriale per la Programmazione Economia).
  • Italian Medicines Agency (AIFA)
  • IZSs (Experimental Zoo prophylactic Institutes)
  • Liga de Enfermos Vizcaínos de Artritis Reumatoide
  • Liga Reumatológica de España
  • Lund University Malmo
  • Medicines and Healthcare products Regulatory Agency (MHRA)
  • Ministerio de Sanidad y Consumo
  • Ministry of Health (Ministero della Salute)
  • National Association of Statutory Health Insurance Physicians
  • National Development and Reform Commission (NDRC)
  • National Institutes for Scientific Research (IRCCSs)
  • National Institutes of Health (NIH)
  • National Pharmaceutical Pricing Authority (NPPA)
  • NEPI Institute
  • NHS Trusts
  • Osasun Teknologien Ebaluazioko Zerbitzua (OSTEBA)
  • Primary Care Trusts (PCTs)
  • Royal Pharmaceutical Society
  • Scottish Medicines Consortium (SMC)
  • Servicio de Evaluación del Servicio Canario de Salud (SCS)
  • State Chambers of Physicians (Landesärztekammer)
  • The Affordable Care Act (ACA)
  • The British National Formulary (BNF)
  • The Care Quality Commission (CQC)
  • The Centre for Medicare and Medicaid Services (CMS)
  • The China Food and Drug Administration (CFDA)
  • The Department of Health and Human Services (HHS)
  • The Department of Health Medicines, Pharmacy and Industry Group (MPIG)
  • The Directorate of Pharmaceutical and Health Products (DGFPS)
  • The Federal Joint Committee of Germany (G-BA)
  • The German Institute for Health Technology Assessment (DAHTA)
  • The Institut national d'excellence en santé et en services sociaux (INESSS)
  • The International Network of Agencies for Health Technology Assessment
  • The Joint Formulary Committee (JFC)
  • The Medicines Utilization Monitoring Centre (OSMED)
  • The Ministry of Human Resources and Social Security (MOHRSS)
  • The National Agency for Medicines and Health Products Safety (ANSM)
  • The National Development and Reform Commission (NDRC)
  • The National Institute for Health Research (NIHR)
  • The National Monitoring Centre for Clinical Trials (OsSC)
  • The National Monitoring Centre for Pharmacovigilance
  • The Office of Fair Trading (OFT)
  • The Patented Medicine Prices Review Board (PMPRB)
  • The Pharmaceutical and Medical Devices Agency (PMDA)
  • The Social Insurance Organization (Deutsche Sozialversicherung)
  • UK's National Institute for Health and Clinical Excellence
  • Unidad de Evaluación de Tecnologías Sanitarias, Comunidad de Madrid (UETS)
  • UnitedHealthcare
  • University of Bremen
  • World Health Organization
Back to Top